| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
|
Flinn, Ian W.
|
|
2016
|
54 |
C |
p. 11-17
7 p.
|
artikel
|
| 2 |
Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study.
|
Imaoka, Hiroshi
|
|
2016
|
54 |
C |
p. 96-103
8 p.
|
artikel
|
| 3 |
Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials
|
Kroep, J.R.
|
|
2016
|
54 |
C |
p. 57-63
7 p.
|
artikel
|
| 4 |
Endocrine disorders among long-term survivors of childhood head and neck rhabdomyosarcoma
|
Clement, S.C.
|
|
2016
|
54 |
C |
p. 1-10
10 p.
|
artikel
|
| 5 |
Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study
|
Ribal, Maria J.
|
|
2016
|
54 |
C |
p. 131-138
8 p.
|
artikel
|
| 6 |
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
|
Michot, J.M.
|
|
2016
|
54 |
C |
p. 139-148
10 p.
|
artikel
|
| 7 |
Impact of surgical staging on prognosis in patients with borderline ovarian tumours: A meta-analysis
|
Shim, Seung-Hyuk
|
|
2016
|
54 |
C |
p. 84-95
12 p.
|
artikel
|
| 8 |
Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?
|
Lambertini, Matteo
|
|
2016
|
54 |
C |
p. 163-164
2 p.
|
artikel
|
| 9 |
Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias
|
Cremers, Eline M.P.
|
|
2016
|
54 |
C |
p. 49-56
8 p.
|
artikel
|
| 10 |
Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients
|
van Wezel, Esther M.
|
|
2016
|
54 |
C |
p. 149-158
10 p.
|
artikel
|
| 11 |
Perioperative treatment and radical cystectomy for bladder cancer – a population based trend analysis of 10,338 patients in the Netherlands
|
Hermans, Tom J.N.
|
|
2016
|
54 |
C |
p. 18-26
9 p.
|
artikel
|
| 12 |
Predicting survival of men with recurrent prostate cancer after radical prostatectomy
|
Dell'Oglio, Paolo
|
|
2016
|
54 |
C |
p. 27-34
8 p.
|
artikel
|
| 13 |
Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time
|
Lunenburg, Carin A.T.C.
|
|
2016
|
54 |
C |
p. 40-48
9 p.
|
artikel
|
| 14 |
Rationale for anti-CD137 cancer immunotherapy
|
Makkouk, Amani
|
|
2016
|
54 |
C |
p. 112-119
8 p.
|
artikel
|
| 15 |
Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care
|
Meulendijks, Didier
|
|
2016
|
54 |
C |
p. 120-130
11 p.
|
artikel
|
| 16 |
Response to ‘Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?’
|
Goldrat, Oranite
|
|
2016
|
54 |
C |
p. 165-166
2 p.
|
artikel
|
| 17 |
Single-nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors
|
Boer, Hink
|
|
2016
|
54 |
C |
p. 104-111
8 p.
|
artikel
|
| 18 |
Small data sets to develop and validate prognostic models are problematic
|
Collins, Gary S.
|
|
2016
|
54 |
C |
p. 167-168
2 p.
|
artikel
|
| 19 |
Small datasets to develop and validate prognostic models may be a necessary evil to study rare tumours
|
Valpione, Sara
|
|
2016
|
54 |
C |
p. 169-171
3 p.
|
artikel
|
| 20 |
Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
|
Pouessel, Damien
|
|
2016
|
54 |
C |
p. 69-74
6 p.
|
artikel
|
| 21 |
Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a ‘chemosensitive’ relapse: A single-arm phase II study (EORTC-08061)
|
Abdelraouf, Fatma
|
|
2016
|
54 |
C |
p. 35-39
5 p.
|
artikel
|
| 22 |
Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities
|
Bournet, Barbara
|
|
2016
|
54 |
C |
p. 75-83
9 p.
|
artikel
|
| 23 |
The use of gene expression profiling and mutation analysis increases the cost of care for patients with carcinoma of unknown primary; does it also improve survival?
|
Prasad, Vinay
|
|
2016
|
54 |
C |
p. 159-162
4 p.
|
artikel
|
| 24 |
Transition guidelines: An important step in the future care for childhood cancer survivors. A comprehensive definition as groundwork
|
Mulder, R.L.
|
|
2016
|
54 |
C |
p. 64-68
5 p.
|
artikel
|
| 25 |
Two cases of immune thrombocytopenia associated with pembrolizumab
|
Le Roy, Audrey
|
|
2016
|
54 |
C |
p. 172-174
3 p.
|
artikel
|
Tijdschrift beschrijving